KPV’s official-record case is primarily mechanistic and nonclinical. FDA said it found no human administration or exposure data by any route.
FDA staff recommended against both forms; PCAC voted favorably on both form-level questions.
FDA reviewed preclinical anti-inflammatory and wound-related evidence and a cadaver-skin permeability study. That is a legitimate research signal, but it remains indirect.
FDA briefing pp. 19–23The key evidentiary break is not simply the absence of a large trial: FDA said it found no human administration or exposure data by any route.
FDA briefing pp. 25–27The committee outcome belongs beside the evidence record—not on top of it. A favorable advisory vote describes the panel’s recommendation on compounding eligibility; it does not erase FDA’s characterization, route-match or human-evidence concerns.
These are attributed testimony arguments, not PeptideBase endorsements. Each one is paired with the most relevant FDA answer and an explicit assessment of what the evidence can—and cannot—carry.
Only named, source-reconciled speaker moments that were checked against the recording appear here. Statements remain attributed arguments unless the underlying evidence was independently established; no machine-caption wording is published as a quotation.
Board-certified urologist; fellowship-trained in male fertility, microsurgery and sexual medicine
Verify credentialsTatem presented KPV as the three-amino-acid end fragment of alpha-MSH and described anti-inflammatory findings from laboratory and animal models. He offered that work as a rationale for clinical interest, not as a human treatment result.
President and Executive Director, Center for Science in the Public Interest; former FDA Associate Commissioner
Verify credentialsLurie said CSPI opposed adding all seven substances. He argued that the FDA criteria had not been met, that compounded products could create consumer risks, and that listing could weaken incentives for development through the standard drug-approval pathway.
Laboratory and animal findings can support biological plausibility. No human-administration result for the nominated KPV forms, routes and uses was established in the record used for this review.
FDA found a lack of evidence to evaluate effectiveness for the nominated uses and a lack of clinical and nonclinical safety information.
FDA Day 1 presentation · 06:12:25The biology explains why KPV merits research. It does not establish a safe human dose, a route-specific safety profile or clinical benefit.
The favorable majority appears to have treated preclinical plausibility and pharmacy controls as enough to recommend a pathway. FDA treated the absence of direct human exposure, effectiveness and safety data as unresolved under the listing criteria.
Editorial inference from the hearing record—not an attributed rationale for every voterThese are recurring propositions in the wider peptide discussion, not attributed speaker quotations.
FDA said the nomination contained no clinical studies and FDA identified no human exposure data for KPV by any route.
Biological origin or relationship to another peptide does not substitute for exposure, pharmacokinetic, immunogenicity or dose-ranging evidence for the exact compounded substance.
FDA identified an in-vitro human-cadaver-skin study reporting low permeability; penetration increased with enhancement techniques.
An in-vitro cadaver-skin result does not establish clinical delivery, effectiveness or systemic safety in living patients.
“Absent” means FDA said it did not identify that evidence within this evaluation. It is not a universal claim that no evidence exists anywhere.
| Evidence question | Status | FDA-record summary | Locator |
|---|---|---|---|
| Human clinical evidence | absent | FDA said it identified no clinical studies or human exposure data for any route. | Briefing pp. 25–27 |
| Nonclinical evidence | indirect | Mechanistic, cell and animal findings were reviewed, but FDA found them inadequate to evaluate the nominated clinical uses. | Briefing pp. 19–24 |
| Exact-form match | limited | The evidence did not establish a complete free-base-versus-acetate clinical record. | Briefing pp. 6–16 |
| Nominated-route match | absent | The nominated route was topical; FDA identified no human administration data. | Briefing pp. 6, 16, 25–27 |
| Evaluated-use match | absent | FDA found no adequate human evidence for wound healing or inflammatory conditions. | Briefing pp. 19–22 |
| Product characterization | limited | FDA considered both forms not well characterized. | Briefing pp. 7–16 |
| Human safety | absent | No human exposure, clinical safety, immunogenicity or aggregation data were identified. | Briefing pp. 25–27 |
| Historical compounding use | limited | FDA found the extent of historical use in compounding unknown. | Briefing pp. 16–19 |
Qualitative evidence map · no numerical score · scoped to FDA’s July 2026 evaluation
A useful dossier should show the reader what evidence could materially strengthen or weaken the current read.
First-in-human safety, pharmacokinetic and dose-ranging evidence
Direct topical studies in the nominated wound and inflammatory uses
Validated reference standards and reproducible release specifications
The official record contains a limited human signal and substantial nonclinical literature, but the exact form, dosage form, route, duration and safety questions remain unresolved.
Open dossierDay 1The central technical issue is identity: FDA treated the seven-amino-acid TB-500 fragment as distinct from full-length thymosin beta-4 and found no direct human TB-500 evidence.
Open dossierDay 1The scientific premise is mitochondrial and metabolic, but FDA said it found no clinical study or human-administration evidence and no adequate nonclinical toxicity package.
Open dossierFree newsletter
The Peptide Research Digest
Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.